Key result
Hospitalization for incident acute heart failure was associated with a ~1 mL/min/1.73 m2 faster decline in eGFR per year over 2 years of follow-up.
Why the study?
Does hospitalization for acute heart failure accelerate the decline in renal function compared to hospitalization for stroke?
Does hospitalization for acute heart failure accelerate the decline in renal function compared to hospitalization for stroke?
Answers are grounded in this paper and cite their sources.
This editorial highlights that hospitalization for acute heart failure is associated with an accelerated decline in renal function, emphasizing the need to identify underlying mechanisms to prevent cardiorenal disease progression.
‘In what circumstances can we pass from this observed association to a verdict of causation? Upon what basis should we proceed to do so?’ Sir Austin Bradford Hill1 It is likely that modern medicine has only scratched the surface of the complex interplay between cardiovascular and renal health. Considerable effort has been devoted to elucidating the impact of worsening renal function on heart failure (HF) and other cardiovascular outcomes.2 Work published this month by Ishigami et al.,3 however, is unique in examining the reverse relationship: the association of incident acute HF (AHF) and cardiovascular disease with faster decline in renal function following hospital discharge. Five years of administrative data and clinical laboratory results for more than a million Swedish citizens in Stockholm were used to compare the slope of estimated glomerular filtration rate (eGFR) 2 years before and after an incident hospitalization for HF, coronary artery disease or stroke (as a reference group).3 Renal function measured during hospitalization or within 3 months before or after hospitalization was excluded to minimize the potential influence of transient changes in renal function. Absolute and relative changes in eGFR before and after hospitalization were compared within individual patients, and subgroup analyses were conducted by renal function, age and sex. The authors3 went to great lengths to leverage the large patient and relatively comprehensive data to examine their findings from multiple angles. They assessed the continuous change in eGFR over time rather than using a dichotomous outcome, which allowed for a more detailed evaluation of relationships with trajectories in renal function after hospitalization. The primary findings are largely consistent across the multiple statistical modelling approaches: hospitalization for incident AHF was associated with a ∼1 mL/min/1.73 m2 faster decline in eGFR per year over 2 years of follow-up. In patients hospitalized for coronary heart disease, eGFR declined ∼0.8 mL/min/1.73 m2 faster after hospitalization; however, the magnitude was attenuated in sensitivity analyses and was not statistically significant among patients with three or more measures of renal function before and after hospitalization. There was no evidence of a faster decline in eGFR after hospitalization for incident stroke. At first glance the absolute magnitude of acceleration in change appears to be small and might not be considered significant on an individual level over the first couple of years. On a population level, however, a faster decline in renal function by even 1 mL/min/1.73 m2 per year rapidly accumulates over time. An increase in eGFR decline of 65–70% per year, approximately the magnitude in this study3 following AHF hospitalization, increases the risk for the development of end-stage renal disease by 30%.4 However, the complex relationship between change in renal function and outcomes among patients with AHF complicates matters. A temporary in-hospital decline in eGFR appears to portend better outcomes as long as it is accompanied by effective decongestion.5, 6 For the patients in this study3 several questions remain unanswered: What events occurred in the hospital? What medications or other treatments were administered? What other conditions, such as infection, occurred? How successful was decongestive therapy? What was the inflammatory profile at presentation and in response to treatment? How did eGFR change during hospitalization?7, 8 For patients hospitalized with AHF in this particular study,3 these unmeasured factors may be potentially important confounders or may play a role in causal pathways. As a result, although there are tantalizing signals for a relationship between incident HF and acceleration of eGFR decline, this study3 cannot address what exactly caused the accelerated decline in renal function among patients hospitalized for AHF or cardiovascular disease. Was the accelerated decline in eGFR attributable to disease progression, factors that precipitated hospitalization, or events occurring during hospitalization? Information on causes of decline in renal function, such as hypotension, medications and inflammation, was not available in the data. One notable finding that may provide a clue as to the mechanism is the lack of acceleration among patients hospitalized with stroke. In both heart disease-related and HF-related hospitalization, decline in myocardial function is a requisite part of the pathophysiology, whether it relates to ischaemia or drives the decompensation in an HF-related hospitalization. Thus the substrate for a negative cardiorenal effect is present. Obviously, in a stroke-related hospitalization, the primary pathophysiology is not myocardial dysfunction. As such, despite other common exposures to antihypertensives such as renin–angiotensin–aldosterone system inhibitors or iodinated contrast agents, the lack of acceleration after hospitalization for stroke may implicate cardiorenal factors in other settings beyond hospitalization. These signals should be considered in the context of the available data and study design. The administrative codes used to construct a cohort and define diagnoses and hospitalization can vary widely within and between providers, coders, hospitals and health care systems. Practice patterns and the utilization of hospitalization and laboratory tests are similarly variable. Time to initiation of haemodialysis and other measures of chronic kidney disease were not assessed in this study.3 Patients were included only if they remained alive for at least 2 years after the index hospitalization in order to ensure that everyone included had the same amount of follow-up time, which may have introduced selection bias through the inclusion of generally healthier patients. Nonetheless, despite these inherent limitations of administrative and clinical data, further clues in the supplemental data may provide insight into several causal questions. What role did medications play in effecting change in renal function? Adjusting for use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers before and after hospitalization had little influence on findings, although we cannot draw conclusions with reference to other medications that may influence renal function. Were sicker patients already at increased risk for an accelerated decline in renal function simply more likely to undergo more frequent assessment of renal function? This issue is more complicated, but the authors3 should be commended for assessing this in multiple sensitivity analyses. Patients hospitalized with AHF had a median of five [interquartile range (IQR) 2–8] serum creatinine measurements while in the study, compared with four (IQR 2–6) for those hospitalized with coronary heart disease, and three (IQR 2–6) for patients hospitalized with stroke. Restricting analyses to patients who had at least three serum creatinine measurements before and after hospitalization attenuated the magnitude of accelerated decline after HF hospitalization, and the relationship after coronary heart disease hospitalization no longer reached the threshold of statistical significance. Although patients with proteinuria prior to hospitalization had a greater absolute decline in eGFR overall, the decline was slower than that in patients without proteinuria prior to hospitalization. It is also worth noting that these findings may not generalize to patient populations with disparities in access to care, or patient populations with significantly different socioeconomic or racial backgrounds. Information regarding race is not available in Stockholm health care administrative data: Swedish law does not allow the recording of information about race; all patients are presumed to be of White European descent, although 27% of adults in Stockholm are immigrants or of non-Swedish background. Although the decision to hospitalize is often treated as an objective ‘hard’ outcome, reasons for hospitalization vary widely among health care systems and are often not related to disease severity. These reasons are not always well described or understood outside the local context. It is therefore possible that patients hospitalized with AHF in Sweden may differ from patients hospitalized for AHF in other countries in important ways that are not evident in the available data. These differences may represent the true underlying drivers of the accelerated decline in renal function, rather than incident development of AHF or cardiovascular heart disease. What is clear is that for patients in Stockholm, hospitalization for AHF and cardiovascular disease are associated with faster decline in renal function. The questions now are: Why? and What can we do to prevent it? Context (the prospective collection of data not available in administrative and clinical data, as well as clear assessment of temporality) is an important key in future work in this area. In order to continue to improve outcomes for patients with AHF and cardiovascular disease, it is important to identify the specific underlying cause of an accelerated decline in renal function. Only then can targets for future interventions be identified and modified in prospective, controlled interventional studies. Conflict of interest: none declared.
No takes yet. Share an insight, caveat, or question.
McNaughton et al. (2020) conducted an editorial in Acute heart failure. Hospitalization for acute heart failure vs. Hospitalization for stroke was evaluated on Change in estimated glomerular filtration rate (eGFR) decline (~1 mL/min/1.73 m2 faster decline per year). Hospitalization for incident acute heart failure was associated with a ~1 mL/min/1.73 m2 faster decline in eGFR per year over 2 years of follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: